In recent years, plants have been increasingly explored for
production of biomedicines and vaccine components. The two main
advantages of plant systems are low cost and a greater potential
for scalability as compared to microbial or animal systems. An
additional advantage from the public health point of view is high
safety compared to animal systems, which is important for vaccine
production: there are no known plant pathogens capable of
replicating in animals, and in humans in particular. A particular
antigen or a protein has to be expressed in a plant using one of
many available platforms; this antigen/protein subsequently needs
to be purified or processed, and later formulated into a vaccine or
a therapeutic; these need to be delivered to a human or animal body
via an appropriate route. Naturally, all these vaccines and
therapeutics must be subjected to regulatory approvals prior to
their use. Thus, the challenge is to adapt plant-based platforms
for production of cost-efficient biomedicals that can be approved
by FDA for use as vaccine components or therapeutics which will be
competitive against existing vaccines and drugs.
This volume attempts to address the entire spectrum of
challenges facing the nascent field of plant-based biomedicals,
from the selection of an appropriate production platform to
specific methods of downstream processing and regulatory approval
issues.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
